Assessing the generalizability of the national lung screening trial: Comparison of patients with stage 1 disease

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 5, 2017, Pages 602-608

  Tanner, Nichole T ^a,b   Dai, Lin ^c   Bade, Brett C ^d   Gebregziabher, Mulugeta ^b,c   Silvestri, Gerard A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidities; Lung cancer screening; Stage 1 lung cancer outcomes

Indexed keywords

AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SMOKING; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL MORTALITY; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; GERIATRIC ASSESSMENT; LUNG TUMOR; MASS SCREENING; PROCEDURES; RISK; STATISTICS AND NUMERICAL DATA; X-RAY COMPUTED TOMOGRAPHY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; RISK; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85029470863     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201705-0914OC     Document Type: Article

References (29)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
2. Hendrick RE, Helvie MA. Mammography screening: A new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol 2012;198:723-728.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
4. Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, Gareen IF, Lynch DA, Marcus PM, Pinsky PF; National Lung Screening Trial Research Team. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 2010;102: 1771-1779.
5. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: The surgical management of primary lung tumors. J Thorac Cardiovasc Surg 2008;135:247-254.
6. El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda SJ, Luketich JD, Landreneau RJ. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: A 13-year analysis. Ann Thorac Surg 2006;82:408-415. [Discussion, pp. 415-416.]
7. Seder CW, Salati M, Kozower BD, Wright CD, Falcoz PE, Brunelli A, Fernandez FG. Variation in pulmonary resection practices between the Society of Thoracic Surgeons and the European Society of Thoracic Surgeons general thoracic surgery databases. Ann Thorac Surg 2016; 101:2077-2084.
8. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-188.
9. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114:675-680.
10. Pinsky PF, Gierada DS, Hocking W, Patz EF Jr, Kramer BS. National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med 2014;161:627-633.
11. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, et al.; National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-253.
12. National Cancer Institute. SEER-Medicare: brief description of the SEER-Medicare Database. 2016 [accessed 2016 Sept 13]. Available from: http://healthcaredelivery.cancer.gov/seermedicare/overview/
13. Wiley LK, Shah A, Xu H, Bush WS. ICD-9 tobacco use codes are effective identifiers of smoking status. J Am Med Inform Assoc 2013; 20:652-658.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
16. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
17. Silvestri GA. Screening for lung cancer: it works, but does it really work? Ann Intern Med 2011;155:537-539.
18. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, et al.; National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980-1991.
19. Meguid RA, Brooke BS, Chang DC, Sherwood JT, Brock MV, Yang SC. Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 2008;85:1015-1024. [Discussion, pp. 1024-1025.]
20. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, Stewart AK. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80:2051-2056. [Discussion, p. 2056.]
21. Bravo Iñiguez CE, Armstrong KW, Cooper Z, Weissman JS, Ducko CT, Wee JO, Martinez MP, Bueno R, Jaklitsch MT, Wiener DC. Thirty-day mortality after lobectomy in elderly patients eligible for lung cancer screening. Ann Thorac Surg 2016;101:541-546.
22. Fernandez FG, Furnary AP, Kosinski AS, Onaitis MW, Kim S, Boffa D, Cowper P, Jacobs JP, Wright CD, Putnam JB Jr. Longitudinal followup of lung cancer resection from the Society of Thoracic Surgeons general thoracic surgery database in patients 65 years and older. Ann Thorac Surg 2016;101:2067-2076.
23. Sancheti MS, Melvan JN, Medbery RL, Fernandez FG, Gillespie TW, Li Q, Binongo JN, Pickens A, Force SD. outcomes after surgery in high-risk patients with early stage lung cancer. Ann Thorac Surg 2016;101:1043-1050. [Discussion, p. 1051.]
24. Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, Bains MS, Downey RJ, Huang J, Isbell JM, et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: A competing risks analysis. J Clin Oncol 2017;35:281-290.
25. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol 2015;16:630-637.
26. Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, et al. Treatment outcomes in stage I lung cancer: A comparison of surgery and stereotactic body radiation therapy. J Thorac Oncol 2015;10: 1776-1784.
27. Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer 2015;121:2341-2349.
28. Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg 2016;152:44-54.e9.
29. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-254.